TR201000689A1 - Sefprozil içeren katı dozaj formlar. - Google Patents

Sefprozil içeren katı dozaj formlar.

Info

Publication number
TR201000689A1
TR201000689A1 TR2010/00689A TR201000689A TR201000689A1 TR 201000689 A1 TR201000689 A1 TR 201000689A1 TR 2010/00689 A TR2010/00689 A TR 2010/00689A TR 201000689 A TR201000689 A TR 201000689A TR 201000689 A1 TR201000689 A1 TR 201000689A1
Authority
TR
Turkey
Prior art keywords
dosage forms
solid dosage
forms containing
cefprozil
containing cefprozil
Prior art date
Application number
TR2010/00689A
Other languages
English (en)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2010/00689A priority Critical patent/TR201000689A1/tr
Priority to PCT/TR2011/000032 priority patent/WO2011093828A2/en
Priority to PCT/TR2011/000036 priority patent/WO2011093831A2/en
Priority to EP11708946A priority patent/EP2528593A2/en
Publication of TR201000689A1 publication Critical patent/TR201000689A1/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Mevcut buluş, sefprozil ve/veya farmasötik olarak kabul edilebilir tuzlarını, hidratlarını, solvatlarını, esterlerini, amorf ve kristal formlarını ve/veya bunların karışımını içeren katı oral farmasötik dozaj formlarına ilişkindir.
TR2010/00689A 2010-01-29 2010-01-29 Sefprozil içeren katı dozaj formlar. TR201000689A1 (tr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
TR2010/00689A TR201000689A1 (tr) 2010-01-29 2010-01-29 Sefprozil içeren katı dozaj formlar.
PCT/TR2011/000032 WO2011093828A2 (en) 2010-01-29 2011-01-28 Solid dosage forms comprising cefprozil
PCT/TR2011/000036 WO2011093831A2 (en) 2010-01-29 2011-01-31 Effervescent formulations comprising cefprozil as active agent
EP11708946A EP2528593A2 (en) 2010-01-29 2011-01-31 Effervescent formulations comprising cefprozil as active agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2010/00689A TR201000689A1 (tr) 2010-01-29 2010-01-29 Sefprozil içeren katı dozaj formlar.

Publications (1)

Publication Number Publication Date
TR201000689A1 true TR201000689A1 (tr) 2011-08-22

Family

ID=44065360

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2010/00689A TR201000689A1 (tr) 2010-01-29 2010-01-29 Sefprozil içeren katı dozaj formlar.

Country Status (3)

Country Link
EP (1) EP2528593A2 (tr)
TR (1) TR201000689A1 (tr)
WO (2) WO2011093828A2 (tr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102357086A (zh) * 2011-11-01 2012-02-22 上海理工大学 一种头孢丙烯口腔崩解片
WO2013109201A1 (en) * 2012-01-18 2013-07-25 Mahmut Bilgic Pharmaceutical compositions comprising cefprozil and clavulanic acid
CN111658616B (zh) * 2020-05-22 2022-03-15 广州白云山医药集团股份有限公司白云山制药总厂 一种头孢丙烯干混悬剂及其制备方法
CN114886859A (zh) * 2022-06-09 2022-08-12 哈尔滨凯程制药有限公司 一种头孢丙烯颗粒剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4520022A (en) 1983-01-28 1985-05-28 Bristol-Myers Company Substituted vinyl cephalosporins
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
CN100417383C (zh) * 2006-03-07 2008-09-10 中国药科大学 一种含有头孢克肟的泡腾片及制法
CN101032489B (zh) * 2006-03-08 2011-06-15 上海秀新臣邦医药科技有限公司 头孢丙烯分散片及其制备方法

Also Published As

Publication number Publication date
WO2011093831A2 (en) 2011-08-04
EP2528593A2 (en) 2012-12-05
WO2011093828A2 (en) 2011-08-04
WO2011093831A3 (en) 2012-02-23
WO2011093828A3 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
MX2019010602A (es) Inhibidores de cdk.
EA201171151A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
MD20140136A2 (ro) Inhibitori ai virusului hepatic C
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
EA201170434A1 (ru) Макроциклические ингибиторы сериновых протеаз гепатита с
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
WO2012030927A3 (en) Modified-release dosage forms of 5-ht2c agonists useful for weight management
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
TW201144301A (en) Processes for preparing linezolid
EA201492287A1 (ru) Дейтерированные производные руксолитиниба
MX345780B (es) Inhibidores triciclicos de girasa.
MY187718A (en) Pharmaceutical formulations
CL2012002716A1 (es) Uso de un compuesto inhibidores de dgat1 porque es útil en la prevención, demora del progreso o el tratamiento de una enfermedad o condición seleccionada a partir de quilomicronemia, síndrome de quilomicronemia familiar e hiperlipoproteinemia tipo v; un compuesto derivado de heteroarilo sustituido; composición farmacéutica.
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
CL2014001861A1 (es) Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
TR201000689A1 (tr) Sefprozil içeren katı dozaj formlar.
TR201000685A2 (tr) Salmeterol ve flutikazon içeren farmasötik preparatlar.
EP2784061A4 (en) ACYLHYDRACO AND OXADIAZOL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF
EP2611799A4 (en) PHARMACEUTICAL COMPOSITIONS OF LINEZOLID
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
HK1225381A1 (zh) 具抗記憶錯誤效果的乙酰膽碱酯酶抑制劑和5-羥色胺受體4(5ht4)激動劑的化合物，其製備方法及其含有的藥物組合物